Monitor FDA non-objection status by May 25, 2026 — a green light could enable near-term commercialization of a dietary supplement, providing early monetization of castanospermine. However, given the company's going-concern uncertainty and lack of manufacturing capacity, any commercial impact remains speculative.
Price Chart
Executive Summary
Sixty Degrees Pharmaceuticals submitted a New Dietary Ingredient Notification (NDIN) to the FDA for a dietary supplement containing Australian Chestnut Extract, with no objection period ending May 25, 2026. The company also secured an option to license a new capsule formulation from Florida State University, expanding its earlier license for large-scale purification of castanospermine.
Key Facts
- Submitted NDIN to FDA for Australian Chestnut Extract on March 11, 2026
- FDA has until May 25, 2026 to object; no objection allows marketing
- Signed option agreement with Florida State University to license capsule formulation technology
- Expanded on January 2026 license for large-scale purification of castanospermine
- Castanospermine is the active constituent and has prior human safety data via celgosivir trials
Financial Impact
No immediate financial impact disclosed; potential long-term revenue if commercialized
Risk Factors
- FDA may object to the NDIN before May 25, 2026
- Company has substantial doubt about its ability to continue as a going concern
- No manufacturing capacity — reliant on third parties for production
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258123 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers